March 17 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS
* Says deal for c$2.3 million
* Taro Pharmaceuticals Inc. (Canada) entered into deal to acquire all issued and outstanding shares of Thallion Pharma
* Consideration would be in cash
* Post deal, no turnover expected of existing products as all revenue-producing assets have been transferred from Thallion to Bellus Health
* Post acquisition of Thallion, Taro Pharma would have only rights for development of orphan drug candidate, Shigamab
* No material effect of acquisition by Taro Pharmaceuticals (Canada) on consol revenue, expenses or profits of co Source text: Further company coverage: SUN.NS